MacroGenics Inc (MGNX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.40+3.53%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MGNX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -86.6% |
| Our one-year growth estimate | diamond | -41.2% |
Growth built into the price is above our model estimate.
The price assumes 45.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
MGNX — officer change
Dated 2026-07-08
Director — Karen Ferrante, M.D.: Dr. Ferrante resigned from the Board for personal reasons.
Why it matters: Initial data will show how well MGC026 works in treating tumors. Positive results could boost confidence in the pipeline.
Supportive ifEarly clinical data for MGC026 shows strong effects against solid tumors.
Worry ifEarly data shows no strong effects against tumors or safety problems.
Why it matters: Completing enrollment will help analyze data quickly. This may move the program forward.
Supportive ifEnrollment in the MGC026 cohorts is completed and shows positive early results.
Worry ifEnrollment is delayed or shows poor patient response rates.
Why it matters: This partnership could enhance cash flow and support the company's financial health.
Supportive ifThey shared news about new progress or money made from the partnership.
Worry ifNo updates or negative news regarding the partnership by Q4 2026.
Why it matters: Sales will decide if MacroGenics gets the $20 million payment.
Supportive ifIf ZYNYZ sales meet or exceed expectations, the company will get the payment.
Worry ifIf ZYNYZ sales fall short of expectations, the company will not get the payment.
Why it matters: The lawsuit results might change how the company makes money and how people see it.
Worry ifGood results in lawsuits that support the company's case.
Less concerning ifBad results or settlements that hurt the company's interests.
Why it matters: Completing enrollment is a step forward in the clinical pipeline. This may attract more attention to MacroGenics.
Supportive ifMGC030 finishes patient enrollment for the Phase 1 study as planned.
Worry ifEnrollment delays or failure to meet the target number of patients for MGC030.
Why it matters: Updates on MGC028 could provide insights into its potential as a treatment option. Positive data may lead to increased interest.
Watch forMGC028 shows good early clinical results in the dose escalation study.
Also watch forMGC028 results show safety issues or that it may not work well.
Why it matters: Filing the IND will help another promising candidate. This may lead to new trials.
Supportive ifThe IND application for MGC030 is submitted on time in Q3 2026.
Worry ifThe IND application is delayed or not submitted as planned.
Why it matters: Extending the cash runway through 2028 is critical for ongoing operations and growth.
Watch forManagement reports a successful funding round or partnership. This will help extend cash.
Also watch forManagement says cash runway is not extended. It may run out before 2028.
Why it matters: The presentation will show how well MGC026 treats tumors. Good results could help investors.
Supportive ifMGC026 has strong anti-tumor effects in the SCCHN group at the ESMO Congress.
Worry ifMGC026 does not show good results or safety issues during the presentation.
Why it matters: Reaching this goal would improve cash flow and help ongoing development.
Supportive ifZYNYZ hits sales that trigger the $20 million milestone payment.
Worry ifZYNYZ sales do not meet expectations, so the milestone payment does not happen.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$252 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $640 loss on $10,000 · 6.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,416 loss on $10,000 · 34.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.